Equitas Small Finance Bank: Schedules Roadshow with Institutional Investors

Equitas Small Finance Bank announced a Non-Deal Roadshow schedule for August 12, 2026. The bank’s representatives will meet with prospective investors, including Janchor Partners, White Oak Capital Management, and Goldman Sachs Asset Management (India) Limited. The roadshow aims to engage with institutional investors. A presentation detailing the bank’s performance and outlook is available on the company’s investor relations website. No Unpublished Price Sensitive Information will be disclosed.

Investor Engagement Schedule Announced

Equitas Small Finance Bank has announced its schedule for a Non-Deal Roadshow, set to take place on Wednesday, August 12, 2026. This initiative is part of the bank’s ongoing efforts to engage with the investment community and provide updates on its performance and strategy. The roadshow is being conducted in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Meetings with Key Investors

The bank’s representatives will be meeting with prospective investors in person during this roadshow. The scheduled meetings include:

  • Janchor Partners
  • White Oak Capital Management
  • Goldman Sachs Asset Management (India) Limited

These meetings are designed to facilitate discussions with key stakeholders in the financial sector. The schedule is subject to potential changes based on the exigencies of the investors or the Bank.

Presentation Available Online

A presentation intended for this Non-Deal Roadshow has been made available on the Equitas Small Finance Bank’s website. Investors can access this presentation at: https://ir.equitas.bank.in/wp-content/uploads/2026/07/ESFB-InvestorPresentation_Q1FY27.pdf. The bank has also clarified that no Unpublished Price Sensitive Information is expected to be shared during these interactions, ensuring transparency and fairness in its investor communications.

Source: BSE

Previous Article

Aarti Pharmalabs: Q1 FY27 Results Show Profit Growth, New MD Appointed

Next Article

Aarti Pharmalabs: Board Approves Q1 FY27 Results, Capacity Expansion, and Leadership Changes